| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:Ar-V7-IN-1
CAS:2230880-25-6
Purity:98% Package:100 mg；50 mg
|
| Company Name: |
Shanghai?Medlife?Pharm-Tech?Co.,?Ltd
|
| Tel: |
021-59167510 18117107507 |
| Email: |
vip@med-life.cn |
| Products Intro: |
Product Name:Ar-V7-IN-1
CAS:2230880-25-6
Purity:>=99% Package:50mg;200mg;100mg;5mg;25mg;10mM*1mLinDMSO;10mg
|
|
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Basic information |
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Chemical Properties |
| Boiling point | 542.8±60.0 °C(Predicted) | | density | 2.12±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO : 83.33 mg/mL (211.45 mM; Need ultrasonic) | | pka | 2.50±0.50(Predicted) | | form | Solid | | color | White to off-white |
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Usage And Synthesis |
| Biological Activity | Ar-V7-IN-1 is a potent inhibitor of Ar-V7. AR-V7 is a hormone-independent splice variant of the androgen receptor. Ar-V7-IN-1 has the potential for the research of various indications, in particular cancers such as prostate cancer (extracted from patent WO2018114781A1, compound 43)[1]. | | References | [1]. Fuqiang Ban, et al. Ar-v7 inhibitors. Patent WO2018114781A1. |
| | 4-(4-(4,5-dibromo-1H-imidazol-1-yl)thiazol-2-yl)morpholine Preparation Products And Raw materials |
|